Wegovy Pill Sustains Weight Loss After Switch From Weekly Injectables

Overview

• The company reported on Sept. 30, 2026 that 194 patients who switched from weekly injectable GLP‑1 drugs to the daily Wegovy pill lost a mean 4.1% of body weight, about 4.0 kg, over three months.
• The analysis was an observational, practice‑based study run with U.S. telehealth provider Ro and relied in part on patient self‑reports, so it cannot prove the pill is superior to injectables.
• Novo has launched the oral Wegovy in the United States, the United Kingdom, Germany and the United Arab Emirates and said oral formulations now make up roughly one‑third of U.S. obesity prescriptions with the company capturing more than 80% of new oral starts.
• Executives say the pill gives Novo commercial momentum after earlier market share losses to Eli Lilly, and the company projects oral therapies could take a large slice of a market analysts expect to reach about $100 billion annually by the decade’s end.
• Clinicians should weigh known gastrointestinal side effects of oral semaglutide, longer‑term efficacy and adherence data, and randomized comparative trials when deciding between daily pills and weekly injections.